Press Releases Johnson & Johnson Xetra

Equities

JNJ

US4781601046

Market Closed - Xetra Other stock markets 16:35:46 03/07/2024 BST			After market 19:33:09
134.4 ^EUR	-1.50%		135.4	+0.73%

04:30pm	Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	MT
02:43pm	Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	DJ

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	01:01pm	AQ
State AG Updates: June 6-13, 2024	07-02	AQ
CHMP adopts positive opinion for BALVERSA for the treatment of adult patients	07-01	AQ
Johnson & Johnson - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class	07-01	AQ
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	06-28	PU
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	06-28	PR
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	06-28	PU
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	06-27	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	06-27	AQ
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	06-25	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	06-24	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	06-21	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	06-21	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	06-20	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	06-20	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	06-20	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	06-18	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	06-17	BU
J&J commits five-year investment in Italian medicine manufacturing	06-17	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	06-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm